Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group Inc. announced the approval of its Aripiprazole Microspheres for Injection by the National Medical Products Administration. This long-acting, sustained-release medication is designed for adult schizophrenia treatment, offering a once-a-month administration that enhances medication adherence and reduces recurrence, hospitalization, and associated economic and social burdens.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a company operating in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in the creation of innovative drug formulations, with a market focus on addressing medical needs such as schizophrenia treatment.
Average Trading Volume: 957,325
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.53B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.